Moderna is trading at $53.95, with a -4.10% change (4.1% down) on August 6, 2026, despite FDA approval of its mFLUSIVA seasonal flu vaccine.

  • The approval covers adults aged 50 and older and is favorable.
  • No fresh negative company-specific catalyst directly explains the decline.
  • Prior norovirus trial setback and Q2 results remain background pressure, while biotech is broadly stronger.